Lutheran Home Of The Good Shepherd in New Rockford, ND

Lutheran Home Of The Good Shepherd is a medicare and medicaid certified nursing home in New Rockford, North Dakota. It is located in Eddy county at 1226 1st Ave N, New Rockford, North Dakota 58356. You can reach out to the office of Lutheran Home Of The Good Shepherd via phone at (701) 947-2944. This skilled nursing facility has 65 federally certified beds with average occupancy rate of 76%. Its legal business name is Lutheran Home Of The Good Shepherd and has the following ownership type - Non Profit - Corporation.

Lutheran Home Of The Good Shepherd (Medicare CCN 355041) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 1978 (46 years certified) and the last quality survey was conducted in March, 2020.

Name	Lutheran Home Of The Good Shepherd
Location	1226 1st Ave N, New Rockford, North Dakota
Certified By	Medicare and Medicaid
No. of Certified Beds	65
Occupancy Rate	76%
Medicare ID (CCN)	355041
Legal Business Name	Lutheran Home Of The Good Shepherd
Ownership Type	Non Profit - Corporation

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Lutheran Home Of The Good Shepherd from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Lutheran Home Of The Good Shepherd are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Lutheran Home Of The Good Shepherd give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Roundup: Advocates watching Calif. budget for Medi-Cal cuts; Mich. AG to appeal same-sex health benefits ruling; Kansas city seeks to extend health care tax

Brown's proposed budget will outline his plans for expanding health coverage under the new federal health care law, which is set to require increased coverage beginning in January 2014. The law will put hundreds of thousands of new enrollees into California's public insurance program, but the governor has raised concerns about what that will cost.

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both "Clusters of excellence", Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects are dedicated to the development of new biological products based on the Lauriad™ technology allowing mucous penetration of a biologically active compound.

Study on identification of novel stem cell population in neuroblastoma to be presented at ANR conference

Dr. Eugene Kim, a pediatric surgeon with Texas Children's Cancer Center and assistant professor of surgery at Baylor College of Medicine (BCM), and Dr. Jason Shohet, chair of the Neuroblastoma Research Program at Texas Children's Cancer Center and associate professor in the Section of Hematology-Oncology at BCM, will speak at the Advances in Neuroblastoma Research (ANR) conference about the identification of a novel stem cell population in neuroblastoma.

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

Read more Medical News

› Verified 9 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	1
Total Amount of Fines in Dollars	$25578
Number of Payment Denials	0
Total Number of Penalties	1

The resident survey data of Lutheran Home Of The Good Shepherd is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	26.18	14.46
Percentage of long-stay residents who lose too much weight	5.73	5.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder	31.63	48.41
Percentage of long-stay residents with a catheter inserted and left in their bladder	0	1.79
Percentage of long-stay residents with a urinary tract infection	1.01	2.65
Percentage of long-stay residents who have depressive symptoms	6.93	5.05
Percentage of long-stay residents who were physically restrained	0	0.23
Percentage of long-stay residents experiencing one or more falls with major injury	4.93	3.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine	100	93.87
Percentage of long-stay residents who received an antipsychotic medication	20.11	14.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine	100	83.88
Percentage of short-stay residents who newly received an antipsychotic medication	0	1.79
Percentage of long-stay residents whose ability to move independently worsened	25.92	17.09
Percentage of long-stay residents who received an antianxiety or hypnotic medication	12.24	19.7
Percentage of high risk long-stay residents with pressure ulcers	2.7	7.32
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine	100	95.98